Drug discovery campaigns need not be limited to strategies with focus on single or strictly defined targets. Instead, target-agnostic programmes utilizing validated phenotypic criteria to detect promising therapy-like activities can deliver candidate hit molecules without underlying assumptions regarding target identities.
At o2h discovery, we have experience across a broad range of assays and cellular models recapitulating disease pathophysiology, which may be used directly in your next phenotypic screen. Additionally, we have utilized and adapted a wide range of techniques and analysis platforms to robustly identify, define and quantify novel phenotypes. From transcript analysis and reporter assays through to live-cell and high-content assays, we can provide the support that will convert a diversity of library candidates into phenotypically-rationalised novel hits.
To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.